arginine has been researched along with everolimus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bedossa, P; Couvelard, A; Cros, J; de Mestier, L; Guedj, N; Hammel, P; Hentic, O; Moati, E; Panis, Y; Paradis, V; Raffenne, J; Ruszniewski, P; Sauvanet, A; Sbidian, E; Svrcek, M | 1 |
| Marik, PE; Vahid, B | 1 |
2 review(s) available for arginine and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
1 other study(ies) available for arginine and everolimus
| Article | Year |
|---|---|
Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
Topics: Aged; Antineoplastic Agents; Arginine; Digestive System Neoplasms; Everolimus; Female; Gene Expression Regulation, Neoplastic; Genotype; Glycine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Polymorphism, Single Nucleotide; Receptor, Fibroblast Growth Factor, Type 4; Retrospective Studies; Signal Transduction; STAT3 Transcription Factor | 2016 |